Alvotech (ALVO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$494.6M

Revenue (quarter)

$105.9M

Revenue growth (year over year)

−38.90%

Gross profit (trailing twelve months)

$300.0M

Gross margin

60.66%

Net income (trailing twelve months)

−$179.6M

Net income (quarter)

−$66.8M

Net income growth (year over year)

−308.57%

Net margin

−36.31%

Return on equity

—

EPS (trailing twelve months)

−$0.62

Book value per share

−$0.54

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

112.06%

Payout ratio

—

Dividend yield

—

Company profile

Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

• Is Alvotech (ALVO) profitable?

  No. Alvotech reported a net loss of $179.6M over the trailing twelve months.

• How much revenue does Alvotech (ALVO) make?

  Alvotech generated $494.6M in revenue over the trailing twelve months, down 38.90% year over year.

• How do I buy stock in Alvotech (ALVO)?

  ALVO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.